1. Introduction
===============

Methyl chloroformate (ClCOOCH~3~, methyl chloroformate) is a raw material for pharmaceutical and insecticidal production. It can be used for the preparation of herbicides, fungicides, and Carbendazim, as well as in the manufacture of biochemical weapons.^\[[@R1]\]^ Methyl chloroformate has strong causticity and is an irritant. It reacts with water or vapor, emits heat and releases toxic caustic gases, which can be inhaled via the respiratory tract, ingested through the digestive tract, and absorbed via the skin. Eyes and respiratory mucosa are extremely irritated by these gases, causing mucous membranes or skin burns, severe poisoning, or pulmonary edema.^\[[@R2]\]^ As the supervision of safety production systems has improved, the occupational protection of manufacturing workers has also improved in recent years, and there have only been a few methyl chloroformate inhalation poisoning cases. This article describes the recent and successful treatment of a patient who experienced acute accidental methyl chloroformate inhalation poisoning, as well as the case studies of 6 poisoning patients from 1989 to 2017 in China. The goal of this paper is that the information described here may help improve the clinical understanding of acute methyl chloroformate poisoning.

2. Case report
==============

A 52-year-old female who worked in a chemical plant presented with a chief complaint of an irritating cough after inhaling toxic fumes accidentally, as well as dyspnea with nausea and vomiting for 16 hours. At 6 [pm]{.smallcaps} on April 9, 2016, the patient inhaled leaked methyl chloroformate gas following a workplace accident. Then, an irritated cough occurred with a lot of white foam phlegm and systemic discomfort. Once out of the toxic environment, no significant improvement in symptoms, and the cough aggravated, followed by chest tightness, wheezing, dyspnea, nausea, vomiting, and the sensation of pharyngeal infarction. Two hours later, she was sent to the local hospital for emergency observation. She was administered oxygen, antiinflammatory medication, and a cough suppressant, but the symptoms still existed. Because the patient did not have hemoptysis, chest pain, or syncope since onset, she was transferred to our hospital the next day.

2.1. Examinations
-----------------

Physical examination and investigation included the following findings: T 36.5 °C, blood pressure 133/79 mm Hg, pulse (P) 119/min, respiratory rate (R) 26/min; soft spirit, painful expression, no skin yellowness, mild oral cyanosis, I° tonsil enlargement, no superficial lymph node enlargement, low respiratory sounds, audible phlegm-ringing and wheezing in right lung, no bulge and no abnormal impulse or thrills in the precordial areas, a normal heart border, regular cardiac rhythm, and no pathological murmur at the valve auscultation area. The physical examination of the abdomen, arms and legs, and nervous system showed no abnormalities. Arterial blood gas analysis provided the following findings: pH 7.417, arterial partial pressure of oxygen (PaO~2~) 51.5 mm Hg, partial pressure of carbon dioxide (PCO~2~) 48.3 mm Hg, HCO~3~^−^ 30.4 mmol/L; white blood cell 12.5 × 10^9^/L, neutrophil (N) 76.1%, red blood test 4.16 × 10^12^/L, PLT 252 × 10^9^/L, hemoglobin 127 g/L, creatinine 58 μmol/L, normal liver function test, PCT 0.092 ng/mL, C-reactive protein 2.45 mg/L, D-dimer 0.52 μg/mL, B-type natriuretic peptide 72.9 pg/mL, and troponin 0.012 ng/mL. The computed tomography (CT) showed scattered multiple lobular solid changes with patchy effusion in the lungs, which appeared to be an inhaled lung injury (Fig. [1](#F1){ref-type="fig"}).

![First computed tomography (CT) examination on April 10, 2016 and the red arrows represent the lesion.](medi-97-e0288-g001){#F1}

2.2. Diagnosis and treatment
----------------------------

The initial diagnoses at hospitalization were acute methyl chloroformate intoxication, acute chemical inhaled lung injury, and type I respiratory failure.

After admission, the patient was subjected to a liquid diet, electrocardiogram monitoring, an oxygen mask, fluid volume recording, electrolyte and vital sign monitoring, and other general treatments. The following pharmacotherapy interventions were administered: methylprednisolone 120 mg b.i.d. (intravenous \[i.v.\], 2 times daily) for edema treatment, merlot-sulbactam sodium 3.75 g q8 h (every 8 hours) and moxifloxacin 0.4 g qd (1 time daily, i.v.) for antiinfection treatment, ambroxol 150 mg q8h (i.v.) to eliminate phlegm, lansoprazole 30 mg q12h (every 12 hours, i.v.) to inhibit gastric acid, and sodium bicarbonate 10 mL plus protease 4000 U q6h (every 6 hours, aerosol inhalation). At the 2nd day after admission, the chest tightness, shortness of breath, and dyspnea were significantly improved, but there was still a sense of obstruction in the throat. The patient\'s mental state clearly improved after 1 week of hospitalization without any complaints. The CT scan showed that the 2 lungs held scattered exudate but were significantly improved (Fig. [2](#F2){ref-type="fig"}). Re-examining the blood gas analysis (nasal tube oxygen 5 L/min) produced the following findings: pH 7.423, PCO~2~ 45.9 mm Hg, PaO~2~ 130.7 mm Hg, and HCO~3~^−^ 29.3 mmol/L. Electronic fiberoptic bronchoscopy examination showed pharyngeal follicular hyperplasia, obvious trachea and bronchial mucosa congestion in both lungs, and a little viscous secretion adhered to the surface. The lumen was unobstructed after suction, with no stenosis, bleeding or new organisms, and no congestion edema in the larynx (Fig. [3](#F3){ref-type="fig"}). Bronchoalveolar lavage was completed on the medial extremity of the right middle lobe. The lavage fluid was colorless and turbid, and the total number of cells was 1100 × 10^6^/L with the following composition (leukocytes 380 × 10^6^/L, Ns 2%, lymphocytes 9%, and macrophages 89%). The bacteria and fungi cultures were negative. The chest CT showed 2 pulmonary scattered exudate areas with dissipation and absorption (Fig. [4](#F4){ref-type="fig"}). Patient\'s follow-up at outpatient on March 2017 and CT examination indicated that the heart and lung were in good function without obvious abnormalities (Fig. [5](#F5){ref-type="fig"}). No abnormality was observed in the electronic bronchoscopy examination (Fig. [6](#F6){ref-type="fig"}). Patient follow-up was completed in an outpatient setting on October 2017, and the CT examination was then compared to the CT from March 2017 (Fig. [7](#F7){ref-type="fig"}).

![Computed tomography (CT) examination on the 2nd day of hospitalization, on April 13, 2016 and the red arrows represent the lesion.](medi-97-e0288-g002){#F2}

![Electronic fiberoptic bronchoscopy examination on April 20, 2016 and the black arrows represent the lesion.](medi-97-e0288-g003){#F3}

![Computed tomography (CT) examination after 1 week of hospitalization, on April 18, 2016.](medi-97-e0288-g004){#F4}

![Computed tomography (CT) examination at outpatient on March 7, 2017.](medi-97-e0288-g005){#F5}

![Electronic bronchoscopy examination at outpatient examination on March 7, 2017.](medi-97-e0288-g006){#F6}

![Computed tomography (CT) examination at outpatient examination on September 11, 2017.](medi-97-e0288-g007){#F7}

3. Discussion
=============

3.1. Retrieving papers about methyl chloroformate poising
---------------------------------------------------------

With "methyl chloroformate" as the key word in Wanfang data, the VIP database and Chinese periodical Full-text Data Base (China National Knowledge Infrastructure) were searched to identify papers published before September 30, 2017. In total, 175 papers were retrieved. After reading, 3 papers were identified approximately 6^\[[@R3]--[@R5]\]^ methyl chloroformate poisoning cases, plus this one, including 4 males and 3 females (Table [1](#T1){ref-type="table"}). With" (\[Chinese\] OR China) AND methyl chloroformate" as the key words in PubMed and Medline, 3 articles were retrieved, but after reading them, none of them truly described cases of methyl chloroformate poising.

###### 

Clinical data of 7 patients with acute chloroformate poisoning.
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3.2. Physical and chemical properties of methyl chloroformate and the mechanism of methyl chloroformate poisoning
-----------------------------------------------------------------------------------------------------------------

Methyl chloroformate is a colorless liquid with a strong irritant odor. Its molecular formula is ClCOOCH~3~. It is slightly soluble in water and soluble in benzene, methanol, ether, and other organic solvents.^\[[@R2]\]^ For its chemical properties of ester, hydrolysis, fermentation, ammonia solution reaction and the like can occur. When heated it can be decomposed into ethanol, hydrochloric acid, and carbon dioxide.^\[[@R6]\]^ Its physical and chemical properties are detailed in Table [2](#T2){ref-type="table"}. After skin and mucosa contact with methyl chloroformate, the main clinical manifestation is the stimulation of the ocular and respiratory tract. Inhaled poisoning can cause pulmonary edema and death.^\[[@R4]\]^ Its mechanism is currently believed to be associated with the aggregation and activation of Ns in the lungs. When an acidic substance is inhaled, some cytokines such as tumor necrosis factor, interleukin-6, and interleukin-8 are released.^\[[@R7],[@R8]\]^ These factors trigger the aggregation and activation of Ns in damaged lung tissues, leading to alveolar capillary bleeding and hyperemia, as well as the accumulation of protein infiltrates in the alveoli. These things contribute to pulmonary edema, while edema fluid simultaneously dilutes the endogenous surfactant. As the surfactant is inactivated and its concentration decreases in the alveoli, atelectasis is aggravated.^\[[@R9]\]^

###### 

General chemical and physical properties of chloroformates.
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3.3. The lung is the main injured target of methyl chloroformate poisoning
--------------------------------------------------------------------------

The 6 reported cases of previous reports, as in this case, were all cough, sputum, dyspnea, etc. as the first symptom. Five patients died from pulmonary edema showed that lung was the main organ suffered from methyl chloroformate poisoning. Some scholars gave the rats methyl chloroformate by static intoxication and found that the main lesions in the lung included the exfoliation of bronchial epithelial cells, edema in the alveolar interstitial area, swelling of the alveolar wall capillary endothelial cells, an increase of pinocytic vesicles, the formation and breakage of vesicles, and the destruction of type I alveolar cells. Twenty-four hours later, when the endothelial cells are damaged to a certain extent, increases of capillary permeability are seen along with the obstruction of microcirculation, which generates increasing capillary pressure. Liquid then extravasates from the blood vessels to give rise to severe pulmonary edema and fibrin deposition through the destruction of the respiratory membrane.^\[[@R10]\]^ Therefore, alveolar septum interstitial edema is considered to be one of the main characteristics of morphological changes of methyl chloroformate poisoning.

3.4. AEGL grading and treatment advances of methyl chloroformate-inhaled toxicity
---------------------------------------------------------------------------------

An acute toxicity test in mice showed that both the exposure time and the inhalation doses are significantly correlated with the severity of the disease (Table [3](#T3){ref-type="table"}). A longer exposure time and higher inhaling concentration are associated with a higher lethal rate, which is consistent with the findings of Hoeschst, etc.^\[[@R6]\]^

###### 

Rat lethal concentration 50% (LC~50~) values (ppm) for methyl chloroformate and their hydrolysis products.
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America Acute Exposure Guideline Level Committee (acute exposure guideline levels \[AEGLs\]) divided methyl chloroformate inhalation poisoning into 3 levels according to the inhaling concentrations in the prescribed exposure time^\[[@R11]\]^: AEGL-1 is exposed to the concentration that may produce obvious discomfort, including irritating or nonspecific symptoms, which are transient and reversible. In this phase, methyl chloroformate symptoms can be alleviated. AEGL-2 refers to the potential for irreversible or other serious, long-term adverse effects that may occur at a higher exposure concentration. AEGL-3 represents an exposure concentration generating life-threatening effects or even death (Table [4](#T4){ref-type="table"}).

###### 

Standards and guidelines for methyl chloroformate.
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AEGL grading is beneficial to determine the severity of disease to improve the prognosis of patients by diverse treatment schemes. Combining the successful treatment of this case, we suggest that:

1.  Poisoned patients should be evacuated from the exposure site immediately, and contaminated clothing should be removed as quickly as possible to reduce poisoning and burn injuries.

2.  Oxygen therapy should be given as early as possible; mask oxygen, mechanical ventilation, and hyperbaric oxygen can all help prevent pulmonary edema. It is worth pointing out that low tidal volume ventilation of mechanical ventilation should be emphasized,^\[[@R12]\]^ as the strong corrosivity of methyl chloroformate can lead to the damage of the alveolar wall and lung tissues, impaired pulmonary compliance, and alveolar elasticity. The pressure of the alveolus will be increased for excessive tidal volume and positive pressure ventilation, which is inclined to cause pneumothorax, barotrauma, and even mediastinal emphysema.

3.  The patients' condition should be evaluated fully. Medical personnel should grasp the occasion and indications of tracheotomy accurately, trying best to avoid tracheal intubation to prevent aggravating the damage to corrosive airway.

4.  Early, adequate, and short-range glucocorticoids should be used to block the inflammatory reaction effectively and prevent pulmonary edema, as described in Pusa et al.^\[[@R13]\]^

5.  Early examination of electronic bronchoscopy, when necessary, and alveolar lavage will help evaluate the pathogenetic condition in a timely manner to adopt an individualized comprehensive treatment. Bai et al^\[[@R14]\]^ suggested that bronchoalveolar lavage is beneficial to clear the harmful substances away and improve the ventilatory function of patients. In this case, the patient underwent bronchoscopy examination in a stable condition. On the one hand, the examination helps to identify the degree of damage of the airway mucosa, strengthening the drainage of secretions. On the other hand, alveolar lavage was used for the bacteria assessment, fungal cultures, and drug susceptibility tests to select effective antibiotics to control pulmonary infection. In addition, regular follow-up of bronchoscopy examination is favorable to reduce the incidence of airway scar stenosis caused by long-termed chemical damage.

6.  Chest CTs should be carried out regularly to master the dynamical changes of pulmonary lesions.

4. Conclusions
==============

There is no special antidote for methyl chloroformate poisoning. The basic handling methods include general treatment and symptomatic support. It should be dealt with as early as possible with comprehensive treatment, such as oxygen therapy, glucocorticoid treatment, antibiotics, and the like to control the development of illness.

All 7 cases were exposed to the poison by not taking protective measures during occupational work or not wearing protective tools at the accident scene. It is essential to strengthen the awareness of occupational protection for workers and to provide protective equipment in the manufacturing process (such as goggles, gas masks, latex gloves, protective clothing, etc.). It is also critical to enhance the consciousness of self-protection and the adaptability of contingencies.
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